[go: up one dir, main page]

DE69635224D1 - 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität - Google Patents

1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität

Info

Publication number
DE69635224D1
DE69635224D1 DE69635224T DE69635224T DE69635224D1 DE 69635224 D1 DE69635224 D1 DE 69635224D1 DE 69635224 T DE69635224 T DE 69635224T DE 69635224 T DE69635224 T DE 69635224T DE 69635224 D1 DE69635224 D1 DE 69635224D1
Authority
DE
Germany
Prior art keywords
pdeiv
cytokin
dihydro
imidazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635224T
Other languages
English (en)
Other versions
DE69635224T2 (de
Inventor
Jean Freyne
Stanislas Diels
Ignacio Andres-Gil
Javier Fernandez-Gadea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE69635224D1 publication Critical patent/DE69635224D1/de
Publication of DE69635224T2 publication Critical patent/DE69635224T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69635224T 1995-04-06 1996-03-28 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität Expired - Lifetime DE69635224T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95200870 1995-04-06
EP95200870 1995-04-06
PCT/EP1996/001393 WO1996031487A1 (en) 1995-04-06 1996-03-28 1,3-dihydro-2h-imidazol-2-one derivatives having pde iv and cytokinin inhibiting activity

Publications (2)

Publication Number Publication Date
DE69635224D1 true DE69635224D1 (de) 2006-02-09
DE69635224T2 DE69635224T2 (de) 2006-06-22

Family

ID=8220175

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635224T Expired - Lifetime DE69635224T2 (de) 1995-04-06 1996-03-28 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität

Country Status (15)

Country Link
US (1) US5869515A (de)
EP (1) EP0832071B1 (de)
JP (1) JP4115519B2 (de)
KR (1) KR100400159B1 (de)
CN (1) CN1103760C (de)
AR (1) AR002984A1 (de)
AT (1) ATE305455T1 (de)
CA (1) CA2216542C (de)
DE (1) DE69635224T2 (de)
ES (1) ES2250988T3 (de)
IL (1) IL117806A (de)
MY (1) MY117936A (de)
TW (1) TW375612B (de)
WO (1) WO1996031487A1 (de)
ZA (1) ZA962753B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
PL194673B1 (pl) * 1996-10-02 2007-06-29 Janssen Pharmaceutica Nv Pochodna 2-cyjanoiminoimidazolu, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna
TR200002801T2 (tr) 1998-04-01 2000-12-21 Janssen Pharmaceutica N.V. PDE IV engelleyici piridin türevleri
TR200909479T2 (tr) 1999-08-21 2012-02-21 Nycomed Gmbh Sinerjistik kombinasyon.
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
AU2005238296A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
WO2006078698A1 (en) * 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
WO2007085357A1 (en) * 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
CA1309096C (en) * 1985-08-13 1992-10-20 Sumitomo Chemical Co., Ltd. Butenoic acid derivatives, and their production and use
US4845233A (en) * 1987-09-11 1989-07-04 Iprx, Inc. Imidazolin-2-ones
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
JP3775684B2 (ja) * 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
AU7267094A (en) * 1993-07-28 1995-02-28 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
JP3056788B2 (ja) * 1994-06-24 2000-06-26 ユーロ−セルティーク，エス．エイ． ホスホジエステラーゼｉｖの阻害化合物および阻害方法

Also Published As

Publication number Publication date
AU697390B2 (en) 1998-10-01
DE69635224T2 (de) 2006-06-22
KR19980703448A (ko) 1998-11-05
TW375612B (en) 1999-12-01
AR002984A1 (es) 1998-05-27
US5869515A (en) 1999-02-09
ATE305455T1 (de) 2005-10-15
WO1996031487A1 (en) 1996-10-10
IL117806A (en) 2000-02-17
IL117806A0 (en) 1996-08-04
CN1103760C (zh) 2003-03-26
MY117936A (en) 2004-08-30
JPH11504003A (ja) 1999-04-06
CA2216542C (en) 2009-01-13
JP4115519B2 (ja) 2008-07-09
KR100400159B1 (ko) 2003-12-31
CN1181073A (zh) 1998-05-06
ES2250988T3 (es) 2006-04-16
EP0832071A1 (de) 1998-04-01
CA2216542A1 (en) 1996-10-10
AU5497996A (en) 1996-10-23
EP0832071B1 (de) 2005-09-28
ZA962753B (en) 1997-10-06

Similar Documents

Publication Publication Date Title
CY2005010I1 (el) Ο - αλκυλιωμενα παραγωγα ραπαμυκινης και η χρηση τους, ιδιαιτερως ως ανοσοκατασταλτικων
DE69619661D1 (de) 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-on-derivate mit pde iv-und cytokin-inhibisender aktivität
NL300295I1 (nl) 3,3-Diarylpropylaminen, de toepassing en bereiding hiervan
NL350016I1 (nl) 3-Aryl-4-hydroxy-delta#3-dihydrofuranon-en 3-aryl-4-hydroxy-delta#3-dihydrothiofenon-derivaten.
EE03486B1 (et) Pürasool-4-üülbensoüüli derivaadid ja nende kasutamine herbitsiididena
HUP0000369A3 (en) 3-thiocarbamoylpyrazole derivatives and their use as pesticides
FI952612L (fi) Oksalyyliaminobentsofuraani- ja -bentsotienyylijohdannaisia
FI940904L (fi) Oksatsolidiinidionijohdannaiset, niiden valmistus ja käyttö
DE59711118D1 (de) Spickeln, Zunehmen und Mindern
DE69831233D1 (de) Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
ZA976222B (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their use.
DK0721457T3 (da) 2',5'-Oligoadenylat-2',3'-cyclophosphater og 2',5'-oligo-adenylater med antipapillomavirusaktivitet
TR199800117A3 (tr) Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.
DE69832184D1 (de) O-substituierte hydroxycumaranonderivate mit antitumoraler und antimetastatischer wirkung
DE68910113D1 (de) Wachstuminhibierendes mittel und dessen verwendung.
DE69424051D1 (de) Rapamycin-derivat mit antimikrobe, antikrebs und immunomodulatorischer aktivität
DK1140835T3 (da) 3,3-biarylpiperidin- og 2,2-biarylmorpholon-derivater
DE69637363D1 (de) 1,3-dihydro-1-(phenylalkenyl)-2h-imidazol-2 on-derivate mit pde iv und cytokin-inhibirendes aktivität
MX9203459A (es) Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
DE69635224D1 (de) 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität
EE03614B1 (et) Pürasool-4-üül-bensoüüli derivaadid ja nende kasutamine herbitsiididena
FI934665L (fi) Aryliden-1-azacykloalkaner och arylalkyl-1-azacyckloalkaner, deras salter, dessa foereningar innehaollande laekemedel och deras anvaendning och framstaellning
DE68919512D1 (de) Chinoxalin-Derivate und antiulzerierendes Mittel.
DE69712425D1 (de) Naphthalin-Derivate, Zwischenprodukte und Verwendungen
ITBS950006A0 (it) Passaverdure perfezionato

Legal Events

Date Code Title Description
8364 No opposition during term of opposition